alfuzosin (SL770499) — Competitive Intelligence Brief

alfuzosin (SL770499) (alfuzosin (SL770499)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Urology.

phase 3 Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Urology Small molecule

Target snapshot

alfuzosin (SL770499) (alfuzosin (SL770499)) — Sanofi. Alfuzosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
alfuzosin (SL770499) TARGET	alfuzosin (SL770499)	Sanofi	phase 3	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
eye drops (Phenylephrin)	eye drops (Phenylephrin)	Medical University of Graz	marketed	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
Doxazosin mysylate GITS	Doxazosin mysylate GITS	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
labetalol intravenous	labetalol intravenous	Haseki Training and Research Hospital	marketed	Alpha-beta adrenergic antagonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Norepinephrine (Levophed)	Norepinephrine (Levophed)	University of Louisville	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor
norepinephrine versus midodrine & octreotide	norepinephrine versus midodrine & octreotide	National Hepatology & Tropical Medicine Research Institute	marketed	Sympathomimetic amine / Alpha-1 adrenergic agonist / Somatostatin analog	Alpha-1 adrenergic receptor / Beta-1 adrenergic receptor / Somatostatin receptor
ephedrine and phenylephrine	ephedrine and phenylephrine	University Hospital, Clermont-Ferrand	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

1. Brian J Lipworth · 1 drug in this class
2. CHU de Quebec-Universite Laval · 1 drug in this class
3. Eli Lilly and Company · 1 drug in this class
4. Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
5. Hospital Authority, Hong Kong · 1 drug in this class
6. Japan Heart Foundation · 1 drug in this class
7. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
8. San Francisco Veterans Affairs Medical Center · 1 drug in this class
9. Sanofi · 1 drug in this class
10. Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class